{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/migraine/how-up-to-date-is-this-topic/update/","result":{"pageContext":{"chapter":{"id":"9560b149-423e-5bf5-8239-ae3f4bc97616","slug":"update","fullItemName":"Update","depth":2,"htmlHeader":"<!-- begin field 2a3115f4-b817-4103-ba19-0f29ac08ecf9 --><h2>Update</h2><!-- end field 2a3115f4-b817-4103-ba19-0f29ac08ecf9 -->","summary":null,"htmlStringContent":"<!-- begin item b3289a5e-7238-4522-b5a9-0d3b9cbc98ba --><!-- end item b3289a5e-7238-4522-b5a9-0d3b9cbc98ba -->","topic":{"id":"b2a19577-fc3a-5b75-948b-7c86424dba8f","topicId":"8d5c9fe8-c317-4160-9aa5-50f3a0456472","topicName":"Migraine","slug":"migraine","lastRevised":"Last revised in October 2020","chapters":[{"id":"f5de766d-b899-5cb2-978f-7194e0cbeaf4","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"57045461-bc73-53e8-9968-49ab778a037a","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"32406f3a-91ba-5801-9ef0-87ad7d9b3133","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"52e6d993-e2b2-59c3-920f-27f34a7ec2eb","slug":"changes","fullItemName":"Changes"},{"id":"9560b149-423e-5bf5-8239-ae3f4bc97616","slug":"update","fullItemName":"Update"}]},{"id":"f6c897d2-fd52-5c54-a91b-1b366dced50e","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"058608e6-7b11-54ed-9d12-69b94ea020cf","slug":"goals","fullItemName":"Goals"},{"id":"95d8aa4b-0bce-5da9-b56a-a612d637a001","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"f9b5443b-1c38-5f3c-be42-3e7fffa429e3","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"d5644cb5-763c-596c-8c47-919fec89ce47","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"92308844-16f7-5eeb-9c0a-ad97a07896ec","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"b97a29bb-bac7-5bc8-907c-210d887086f2","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"986db6f6-7568-5e6e-8095-5ce116d22307","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"b6d1719e-8f6a-509b-90d2-7d1f38e19b05","slug":"definition","fullItemName":"Definition"},{"id":"e35d9975-5859-5454-9539-fab1a8ca6a43","slug":"causes","fullItemName":"Causes"},{"id":"3d8350c0-8bc5-5793-a577-411bc703d36f","slug":"prevalence","fullItemName":"Prevalence"},{"id":"eea7fb2e-ce45-5fa7-9ff5-5399f8305dd7","slug":"prognosis","fullItemName":"Prognosis"},{"id":"ad3ec7a1-a418-5232-b554-b202784e3f46","slug":"complications","fullItemName":"Complications"}]},{"id":"23b2a2ec-5694-51eb-97af-5e80f8d0b792","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"86e96919-af81-53dc-805a-36533fa27637","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"1b00b35a-f7c5-5dc3-bd7d-6e72a973af14","slug":"assessment","fullItemName":"Assessment"},{"id":"33c2a435-70da-50e9-b336-2d81b68f99c9","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"1ece6bbf-1986-5392-be1d-427e9603f26a","fullItemName":"Management","slug":"management","subChapters":[{"id":"eb14162e-c87a-5ca7-8eda-4acb5c336298","slug":"adults","fullItemName":"Scenario: Adults"},{"id":"3bced75d-3a79-536f-976d-875a40bf1a8d","slug":"young-people-aged-12-17-years","fullItemName":"Scenario: Young people aged 12-17 years"},{"id":"604f5c24-3920-5626-893b-9c27575decc6","slug":"pregnant-or-breastfeeding-women","fullItemName":"Scenario: Pregnant or breastfeeding women"}]},{"id":"8e2844f3-6843-5776-a5a1-59b0cabc5b93","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"d1661673-77b9-587b-94ce-e5b6ff9de8c5","slug":"drugs-for-acute-migraine","fullItemName":"Drugs for acute migraine"},{"id":"b69cd3a2-8118-552d-ba35-c7db1a498617","slug":"drugs-for-the-prevention-of-migraine","fullItemName":"Drugs for the prevention of migraine"}]},{"id":"daf55050-4154-5b6d-b8ab-0f86775d1038","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"0fbeb3e2-26df-5d63-a045-8af31aed07ef","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"88a22f7c-7eb4-5b57-a406-ab204723d6c0","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"596ed3f2-0ac4-5fd9-9046-b304311543ee","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"c4597510-7ec3-5f98-b5a5-3ef55cd51b5e","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"79a12dcb-038c-5fd4-a311-648c3ee61102","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"41030681-d726-58c4-b509-29748e404597","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"9a8a7e48-db76-50eb-a585-96fe1b4a5977","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"32406f3a-91ba-5801-9ef0-87ad7d9b3133","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"fe45f391-34d4-5d3a-b4da-c081b3a320c0","slug":"new-evidence","fullItemName":"New evidence","depth":3,"htmlHeader":"<!-- begin field 5f4eff11-240c-44df-9455-40b74ad6486c --><h3>New evidence</h3><!-- end field 5f4eff11-240c-44df-9455-40b74ad6486c -->","summary":null,"htmlStringContent":"<!-- begin item abc00525-92cb-4c51-b555-ad391b52e343 --><!-- begin field 098ce421-b58e-44b5-8923-6170c749fbe5 --><h3>Evidence-based guidelines</h3><!-- end field 098ce421-b58e-44b5-8923-6170c749fbe5 --><!-- begin field 000cfed3-20f4-4d89-a221-0669ba6e83f4 --><ul><li>NICE (2020) <em>Galcanezumab for preventing migraine.</em> National Institute for Health and Care Excellence. <a href=\"https://www.nice.org.uk/\" data-hyperlink-id=\"c8b993db-7370-425b-9de1-ac7900c1f0e9\">www.nice.org.uk</a> [<a href=\"https://www.nice.org.uk/guidance/ta659\" data-hyperlink-id=\"f047b1f6-b793-4acb-a466-ac7900c1f10d\">Free Full-text</a>]</li></ul><!-- end field 000cfed3-20f4-4d89-a221-0669ba6e83f4 --><!-- begin field bdde6e12-e40f-4d38-8411-eda32f8fb64e --><h3>HTAs (Health Technology Assessments)</h3><!-- end field bdde6e12-e40f-4d38-8411-eda32f8fb64e --><!-- begin field fbbb9572-f447-4e28-971d-98b5fc24e7d7 --><p>No new HTAs since 1 March 2019.</p><!-- end field fbbb9572-f447-4e28-971d-98b5fc24e7d7 --><!-- begin field 5b45a066-3571-4482-8e26-c68b23f16195 --><h3>Economic appraisals</h3><!-- end field 5b45a066-3571-4482-8e26-c68b23f16195 --><!-- begin field 02391e1e-a7ab-4a1d-9853-8ac880dfd6d3 --><p>No new economic appraisals relevant to England since 1 March 2019.</p><!-- end field 02391e1e-a7ab-4a1d-9853-8ac880dfd6d3 --><!-- begin field 30574484-c09f-4f45-bdac-e03640e10bd2 --><h3>Systematic reviews and meta-analyses</h3><!-- end field 30574484-c09f-4f45-bdac-e03640e10bd2 --><!-- begin field c1ea3ecf-cfae-4a3e-8f33-47e86452eab9 --><ul><li>Vetvik, K.G., MacGregor, E.A. (2021) <em>Menstrual migraine: a distinct disorder needing greater recognition.</em> Lancet Neurology. <a href=\"https://www.thelancet.com/\" target=\"_blank\" rel=\"noopener\" data-hyperlink-id=\"049795cb-2213-46f8-8ef6-acd400b91c22\">www.thelancet.com</a> [<a href=\"https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(20)30482-8/fulltext\" target=\"_blank\" rel=\"noopener\" data-hyperlink-id=\"b11c429b-8b37-48c3-8129-acd400b91c22\">Abstract</a>]</li></ul><!-- end field c1ea3ecf-cfae-4a3e-8f33-47e86452eab9 --><!-- begin field 8b5dd9d0-21b9-4171-aae4-eb366128430c --><h3>Primary evidence</h3><!-- end field 8b5dd9d0-21b9-4171-aae4-eb366128430c --><!-- begin field 88c6a9e0-dec8-400b-9860-da73fe073f04 --><p>No new randomized controlled trials published in the major journals since 1 March 2019.</p><!-- end field 88c6a9e0-dec8-400b-9860-da73fe073f04 --><!-- end item abc00525-92cb-4c51-b555-ad391b52e343 -->","subChapters":[]},{"id":"ae1a75ef-0e7f-55ed-b4ee-ce87ab9e836e","slug":"new-policies","fullItemName":"New policies","depth":3,"htmlHeader":"<!-- begin field 0ec8ed5a-bb76-43a7-9942-28fe46f89829 --><h3>New policies</h3><!-- end field 0ec8ed5a-bb76-43a7-9942-28fe46f89829 -->","summary":null,"htmlStringContent":"<!-- begin item cce6b51a-8465-43da-9f93-d46cd23bddff --><!-- begin field b990b084-7f81-4485-ae7b-1f9a359eda93 --><p>No new national policies or guidelines since 1 March 2019.</p><!-- end field b990b084-7f81-4485-ae7b-1f9a359eda93 --><!-- end item cce6b51a-8465-43da-9f93-d46cd23bddff -->","subChapters":[]},{"id":"4e9b92be-71b9-550e-9010-3f9ff423177f","slug":"new-safety-alerts","fullItemName":"New safety alerts","depth":3,"htmlHeader":"<!-- begin field 5d71b679-d752-4a8b-b38f-cf1fc75441c5 --><h3>New safety alerts</h3><!-- end field 5d71b679-d752-4a8b-b38f-cf1fc75441c5 -->","summary":null,"htmlStringContent":"<!-- begin item 79bad756-9333-4f67-83eb-a2dbadbb1e99 --><!-- begin field 965659fd-dd7a-487e-94bc-bb5e2eb35d42 --><p>No new safety alerts since 1 March 2019.</p><!-- end field 965659fd-dd7a-487e-94bc-bb5e2eb35d42 --><!-- end item 79bad756-9333-4f67-83eb-a2dbadbb1e99 -->","subChapters":[]},{"id":"361b0ca4-3c20-5e4d-9e21-55fd41860408","slug":"changes-in-product-availability","fullItemName":"Changes in product availability","depth":3,"htmlHeader":"<!-- begin field d3b5e5e0-f39d-4cc8-8e03-ac0f86d72ce2 --><h3>Changes in product availability</h3><!-- end field d3b5e5e0-f39d-4cc8-8e03-ac0f86d72ce2 -->","summary":null,"htmlStringContent":"<!-- begin item 71f34d51-f32f-42c9-bd8e-730b465ee5c1 --><!-- begin field 22303d6e-4189-4d4b-a772-2b271dca8c8b --><ul><li>Fremanezumab is recommended for use in adults, only if migraine is chronic (15 or more headaches days per month for more than 3 months with eight or more of those having features of migraine), and if three or more preventative drug treatments have failed. It should be stopped if the migraine frequency does not reduce by 30% or more after 12 weeks. See more <a href=\"https://www.nice.org.uk/guidance/ta631\" data-hyperlink-id=\"afea53b9-89a0-4246-8859-abd10099b8e3\">here</a>. </li><li>Erenumab (Aimovig®) accepted for restricted use within NHSScotland - The SMC has accepted erenumab for prophylaxis of migraine in adults who have at least 4 migraine days per month. Use is restricted to patients with chronic migraine in whom at least 3 prior prophylactic treatments have failed. See more <a href=\"https://www.scottishmedicines.org.uk/medicines-advice/erenumab-aimovig-full-submission-smc2134/\" data-hyperlink-id=\"1500c1f2-fd72-4ebf-9c0f-aa5500ce83a0\">here</a>.</li><li>Ajovy (fremanezumab) is licensed for prophylaxis of migraine in adults who have at least 4 migraines per month. See more <a href=\"https://www.medicines.org.uk/emc/product/11630/smpc\" data-hyperlink-id=\"d9b34fe8-e468-4374-8ad7-abfb00f8d553\">here</a>. </li><li>Erenumab, fremanezumab, and galcanezumab are new monoclonal antibodies that target calcitonin gene-related peptide and are licensed for migraine prophylaxis in adults who have at least four migraine days per month. See more <a href=\"https://dtb.bmj.com/content/58/10/151\" data-hyperlink-id=\"8b2e70e1-260a-48b5-94fd-ac4800a98b28\">here</a>.</li><li>In draft guidance, NICE recommends erenumab for preventing migraine in adults, only if: they have four or more migraine days a month; at least three preventative drug treatments have failed; the 140 mg dose of erenumab is used and it is provided according to the commercial arrangement. See more <a href=\"https://www.nice.org.uk/guidance/gid-ta10302/documents/final-appraisal-determination-document-2\" target=\"_blank\" rel=\"noopener\" data-hyperlink-id=\"6fe5b1c5-3845-4fe9-a0ed-ac9500b24207\">here</a>.</li></ul><!-- end field 22303d6e-4189-4d4b-a772-2b271dca8c8b --><!-- end item 71f34d51-f32f-42c9-bd8e-730b465ee5c1 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}